O13-6 Japanese subgroup analysis of datopotamab deruxtecan in NSCLC cohort of TROPION-PanTumor01, a phase 1 study

Toshio Shimizu,Satoru Kitazono,Edward B. Garon,Melissa L. Johnson,Aaron Lisberg,Alexander Spira,Noboru Yamamoto,Rebecca S. Heist,Jacob M. Sands,Funda Meric-Bernstam,Yoshitaka Zenke,Noriko Yanagitani,Jonathan Greenberg,Fumiaki Kobayashi,Yui Kawasaki,Kiyotaka Yoh

Annals of Oncology（2022）

引用 0|浏览9

暂无评分

摘要

Datopotamab deruxtecan (Dato-DXd) is an antibody drug conjugate composed of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to a topoisomerase I inhibitor via a tetrapeptide-based cleavable linker. Dato-DXd demonstrated encouraging antitumor activity in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) from primary analysis results of TROPION-PanTumor01 (Garon E et al., WCLC2021). Here we report Japanese subgroup data from the NSCLC cohort of TROPION-PanTumor01.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要